Summary
Tarsus Pharmaceuticals (TARS) has shown strong technical indicators, including a 48.35% gain since the Trend Seeker buy signal on 9/4 and 173.43% gain in the last year.
The company focuses on novel eye care therapeutics, with its lead product XDEMVY targeting blepharitis caused by Demodex mites and other promising candidates in development.
Fundamental factors are robust, with a market cap of $2.12 billion and expected revenue growth of 898.49% this year and 78.44% next year.
-
Wall Street analysts are bullish with 8 strong buy ratings, although MorningStar considers the stock 25% overvalued; investors should follow disciplined risk
management.
